Pete G, Hu Y, Walsh M, Sowers J, Dunbar J C
Department of Physiology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Proc Soc Exp Biol Med. 1996 Nov;213(2):187-92. doi: 10.3181/00379727-213-44049.
The insulin-like growth factor-I (IGF-I) and its receptors are widely distributed in peripheral vascular tissue, yet their role in the regulation of blood pressure and blood flow remains unknown. This study investigated the effect of IGF-I on blood pressure and selected regional blood flow in normal Wistar rats anesthetized with chloralose/urethane. The femoral artery was cannulated and used to monitor arterial blood pressure. Electromagnetic flow probes were placed around the left common iliac artery, left renal artery, and the superior mesenteric artery, and used to measure blood flow. IGF-I (2.6 micrograms, 5.1 or 10.3 nmol/animal Iv) was injected as a bolus into the femoral vein. Following the injection of IGF-I (10.3 nmol), we observed a significant decrease of plasma glucose (57%) and a significant decrease of mean arterial pressure (MAP) that continued to decline throughout the 60-min experimental period. IGF-I (5.1 nmol) significantly decreased blood glucose by 44% and decreased the MAP by 14% with a nadir at 15 min and recovery after 60 min. A smaller dose of IGF-I (2.6 nmol) did not significantly decrease the blood glucose but resulted in a slight but significant decrease in MAP. The heart rate was increased by 10.3 and 5.1 but not 2.5 nmol of IGF-I. IGF-I (10.3 nmol) was associated with regional vascular responses with a preferential increase in flow of the iliac and superior mesenteric vessels, measured as vascular conductance. IGF-I (5.1 and 2.6 nmol) increased preferentially renal vascular conductance. Preinfusion with L-NAME, a nitric oxide inhibitor, inhibited the effects of IGF-I on flow. We conclude that IGF-I can selectively dilate vascular beds leading to a decrease in blood pressure and that the response to IGF-I is mediated by nitric oxide.
胰岛素样生长因子-I(IGF-I)及其受体广泛分布于外周血管组织中,但其在血压和血流调节中的作用尚不清楚。本研究调查了IGF-I对用氯醛糖/乌拉坦麻醉的正常Wistar大鼠的血压和选定局部血流的影响。将股动脉插管用于监测动脉血压。将电磁血流探头放置在左髂总动脉、左肾动脉和肠系膜上动脉周围,用于测量血流。将IGF-I(2.6微克、5.1或10.3纳摩尔/动物,静脉注射)作为 bolus 注入股静脉。注射IGF-I(10.3纳摩尔)后,我们观察到血浆葡萄糖显著降低(57%),平均动脉压(MAP)显著降低,且在整个60分钟的实验期间持续下降。IGF-I(5.1纳摩尔)使血糖显著降低44%,MAP降低14%,在15分钟时达到最低点,60分钟后恢复。较小剂量的IGF-I(2.6纳摩尔)未显著降低血糖,但导致MAP略有但显著降低。心率在注射10.3和5.1纳摩尔的IGF-I时增加,但在注射2.5纳摩尔时未增加。IGF-I(10.3纳摩尔)与局部血管反应相关,以血管传导率衡量,髂血管和肠系膜上血管的血流优先增加。IGF-I(5.1和2.6纳摩尔)优先增加肾血管传导率。预先注射一氧化氮抑制剂L-NAME可抑制IGF-I对血流的影响。我们得出结论,IGF-I可选择性扩张血管床导致血压降低,并且对IGF-I的反应由一氧化氮介导。